BiotechTube

daraxonrasib + docetaxel

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC (Non-small Cell Lung Cancer)

Conditions

NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)

Trial Timeline

May 6, 2025 → Dec 1, 2030

NCT ID
NCT06881784

About daraxonrasib + docetaxel

daraxonrasib + docetaxel is a phase 3 stage product being developed by REVOLUTION Medicines for NSCLC (Non-small Cell Lung Cancer). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06881784. Target conditions include NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06881784Phase 3Recruiting

Competing Products

20 competing products in NSCLC (Non-small Cell Lung Cancer)

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
74
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
BBP-398 + osimertinibLianBioPhase 1
25
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
33
YH42946YuhanPhase 1/2
41
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
41
DS-1205c + OsimertinibDaiichi SankyoPhase 1
33
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
77
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
52
gilteritinibAstellas PharmaPhase 1
33
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
naquotinib + midazolamAstellas PharmaPhase 1
33
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
52
ExisulindAstellas PharmaPhase 1/2
41
naquotinibAstellas PharmaPhase 1
33
ASP8273Astellas PharmaPhase 2
52

Other Products from REVOLUTION Medicines

daraxonrasibPhase 3
74
RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Liposomal irinotecan + 5-fluorouracil + leucovorin + OxaliplatinPhase 3
74
RMC-6291 + RMC-6236 + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + RMC-9805Phase 1/2
38
Elironrasib + DaraxonrasibPhase 1/2
38
TNG462 + RMC-9805 + RMC-6236 + mFOLFIRINOX + gemcitabine/nab-paclitaxelPhase 1/2
38